A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer two dose schedules

Martino, Silvana; Samal, Bohumil A.; Singhakowinta, Amnuay; Yoshida, San; MacKenzie, Michael; Jain, Jitender; Vaitkevicius, Vainutis K.

doi:10.1007/bf00390472

Cited by 39 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yap et al (1978) found no responders in 26 patients treated with either 100mgm-2 q 3-4 weekly or 20mgm-2 daily x 5, q 4 weekly. Ostrow et al (1980) (Forastiere et al, 1982;Martino et al, 1984;Bajorin et al, 1987). These studies are summarised in Table I which shows only ten responders out of 113 patients (overall response rate 9%).…”

Section: Cisplatinmentioning

confidence: 99%

Cisplatin and its analogues in the treatment of advanced breast cancer: a review

Smith

Talbot²

1992

Br J Cancer

View full text Add to dashboard Cite

Section: Cisplatinmentioning

confidence: 99%

Cisplatin and its analogues in the treatment of advanced breast cancer: a review

Smith

Talbot²

1992

Br J Cancer

View full text Add to dashboard Cite

“…Carboplatin also has activity in the first-line setting (Table 1) [7][8][9][10][11][12][13][14][15][16]. Four studies of the drug as initial chemotherapy reveal an overall RR of 31% (27 of 85 patients responded).…”

Section: Overview Of Platinum Agents In Breast Cancermentioning

confidence: 99%

“…Nevertheless, the activity of the combination is promising, and it is recommended (given the GI toxicity at higher doses) that further work be undertaken using 75 mg/m 2 of both agents. The combination of taxanes/platinum as chemotherapy for breast cancer has been studied by other investigators (Table 3) [7] No 33/66 (50%) Sledge [9] No Yap [10] Yes Ostrow [7] Yes Forestiere [7] Yes 10/113 (9%) Martino [11] Yes Bajorin [12] Yes…”

Section: Platinum/docetaxel Combinations In Breast Cancermentioning

confidence: 99%

Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer

Crown

2001

The Oncologist

View full text Add to dashboard Cite

Many active nonanthracycline-containing regimens are emerging from clinical trials and may offer the option of treating metastatic breast cancer without resorting to doxorubicin or analogues. When used first-line in metastatic breast cancer, both cisplatin and carboplatin are active agents and hence candidates for combination therapy. In a dose-finding study in patients with no prior chemotherapy for metastatic disease, docetaxel administered together with cisplatin produced a promising response rate (RR) of 60% (73% in patients without prior adjuvant chemotherapy). The combination is feasible, although adequate hydration and antiemetic medication must be given. There is also an early indication that it may be possible to dramatically cytoreduce disease in patients with locally advanced breast cancer who are treated with docetaxel plus cisplatin. Given its lower toxicity, carboplatin may also have a role in combination with the taxanes. Of the nonplatinum agents, vinorelbine appears to hold promise; its combination with docetaxel produced an RR of 59% in a group of anthracycline-pretreated patients with progressive disease. Forty-two percent of the patients studied also had prior exposure to a taxane. Weekly gemcitabine plus monthly docetaxel is feasible and active, as is the combination of docetaxel q 3 weeks with daily oral capecitabine. The Oncologist 2001;6(suppl 3):17-21The Oncologist 2001;6(suppl 3):17-21 www.TheOncologist.com Correspondence: John Crown, M.D., Elm Park, St. Vincent's Hospital, Dublin 4, Ireland. Telephone: 353-1-202-4839; Fax: 353-1-283-7719; e-mail: john.crown@icorg.ie Received February 6, 2001; accepted for publication March 5, 2001. ©AlphaMed Press 1083-7159/2001 INTRODUCTIONEvidence to date suggests that docetaxel is one of the most active single agents in metastatic breast cancer [1,2]. Docetaxel has been shown to be superior to doxorubicin in the treatment of patients with prior exposure to an alkylating agent-containing regimen, and it is also superior to mitomycin/vinblastine and methotrexate/5-fluourouracil (5-FU) in patients whose cancer had progressed following anthracycline therapy [3][4][5][6]. The latter finding is of particular relevance to designers of combination regimens in that it indicates at least a degree of non-cross-resistance between docetaxel and doxorubicin, and the use of these two drugs in combination thus seems logical. In two Breast Cancer International Research Group studies, docetaxel-doxorubicin combinations were superior to more traditional anthracycline-alkylating agentbased combinations. However, the increasing use of anthracyclines in the adjuvant setting mandates the development of nonanthracycline-containing, docetaxel-based combinations.

show abstract

“…It results in exposing patients to new agents when their tumor burden is high, their performance status is poor, their tumor has demonstrated resistance to other treatments, and their bone marrow reserve is limited due to previous therapy. Further, review of reports of phase II agents studied in this sequence demonstrates the frequent occurrence of 'early deaths', making it difficult to give new agents an adequate trial [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer

Martino

Samal

Redman

et al. 1990

Breast Cancer Res Tr

Self Cite

View full text Add to dashboard Cite

With the objective of identifying new chemotherapeutic agents active against breast cancer, we administered the phase II agent deoxydoxorubicin (DxDx) to 25 patients who had received no prior chemotherapy for their metastatic breast cancer. A dose of 30-35 mg/M2 given at 3 week intervals resulted in a response rate of 12%. The patients were subsequently treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide, and prednisone. A response rate of 38% was achieved with this combination as second line therapy. Toxicity of DxDx was predominantly hematopoietic. One patient developed congestive heart failure. Median survival from onset of treatment with DxDx was 39 weeks. DxDx appears to be minimally active against metastatic breast cancer. Whether the administration of phase II agents as first line therapy offers an advantage in the overall management of metastatic cancer, needs further evaluation.

show abstract

A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer two dose schedules

Cited by 39 publications

References 3 publications

Cisplatin and its analogues in the treatment of advanced breast cancer: a review

Cisplatin and its analogues in the treatment of advanced breast cancer: a review

Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer

Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer

Contact Info

Product

Resources

About